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pertension, serum cholesterol, and diabetes mellitus decreases the risk of Parkin-
son’s disease (PD). We therefore examined the epidemiologic association of PD
with hypertension, serum total cholesterol, and diabetes mellitus by conducting a
detailed meta-analysis of all studies published regarding this subject.METHODS:A
systematic comprehensive literature search was performed using PubMed,
EMBASE, and CINAHL (until March 2012) for observational cohort and case-control
studies using relevant keywords. Pooled relative risk (RR) was calculated using
random effects model. Pre specified subgroup analysis was performed to assess the
source of heterogeneity, according to study design, number of covariates adjusted
and adjusted for BMI and cardiovascular diseases. Subgroup and sensitivity anal-
ysis were also done. Heterogeneity and publication bias were also assessed.
RESULTS: 24 studies were included in the analysis. The pooled risk ratio of PD due
to hypertension (n8) was 0.78 (95% CI, 0.67-0.92, I271.85%), due to high serum
cholesterol (n7) was 0.95 (95% CI, 0.77-1.17, I2 75.86%), and due to diabetes
(n14) was 0.94 (95% CI, 0.76-1.16, I2 89.62%). Subgroup analysis showed a signif-
icant difference in effect estimate pooled by cohort and case-control studies (Pin-
teraction0.001). Pooled analysis of cohort studies for diabetes showed a pooled
risk ratio of 1.34 (95%CI, 1.12-1.60, I276.77%). We found no significant difference in
any subgroup analysis. CONCLUSIONS: We found evidence of significant inverse
associations of hypertension, hypercholesterolemia, and diabetes mellitus with
the risk of PD. Further well-designed investigations of the association of vascular
risk factors with the risk of PD are needed, particularly large-scale prospective
studies.
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OBJECTIVES: Technological developments allow remote monitoring of patients
and improve diabetes care. A mobile phone telemonitoring system (TM) might
improve the ability of DM patients to engage in treatment. The objective is to
estimate the annual costs that implementing a TM for glycaemic control in DM
patients might represent to the National Health System and to society in Spain.
METHODS: First, a systematic review of the literature was conducted to determine
cost drivers in DM TM. Electronic databases were searched to identify national and
international clinical and economic articles, published between January, 2001 and
December, 2011, reporting on the clinical benefits, health resources used and costs
associated to DM TM. Second, based on the data gathered, and adapted for Spain,
and on the assumption that TM favors treatment compliance, a mathematical
model was applied to determine the variation in costs associated to macro and
micro DM complications risk reduction derived from hypothetically reaching 100%
DM treatment compliance in groups of patients: compliant, noncompliant and
complications are undiagnosed. RESULTS: A total of 3.539 articles were identified;
48 were reviewed. TM decreases emergency visits (83%), disease related hospital
admissions (75%), length of hospital admission (51%), visits to the outpatient clinic
(40%) and to the specialist (19%). Reduction of indirect costs reaches 120.82 €per DM
patient/year due to less travel expenses (-6.30 €/visits) and productivity gain (-54
€/visits). Assuming that 100% of uncompliant DM patients become compliant (n 
1,550,634 patients) costs associated to macro- and micro-vascular complications
decreases by 5,500 € (€, 2011) million per year. Higher cost reductions are obtained
in the most prevalent vascular complications. CONCLUSIONS: These preliminary
results show that TM in DM patients reduces direct and indirect costs. Significant
costs reduction can be reached if DM treatment compliance is improved with TM in
Spain.
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OBJECTIVES: To carry out a clinical-economic analysis of MoliCare® Premium ex-
tra soft diapers application efficiency for contact dermatitis* and pressure ulcers
prophylaxis with immobile urinary-incontinent patients.METHODS: Estimation of
typical management practice with immobile urinary-incontinent patients’ having
developed contact dermatitis* or pressure ulcers was performed by means of ex-
perts’ questioning. Only direct medical costs were taken into account in the re-
search. A comparative clinical-economic analysis was performed using Markov’s
model. A sensitivity analysis was performed taking into account retail and whole-
sale prices for absorbing means and skin care agents. RESULTS: Twenty weeks’
total costs calculated with Markov’s model use for contact dermatitis* and 1-4
degree pressure ulcers prophylaxis and treatment with one immobile urinary-
incontinent patient with absorbent means and skin care agents’ application were
5508 € in retail prices and 5276 € in wholesale prices; without their application the
costs were 7 446 €. Overall this Analysis shows that medical-prophylactic institu-
tions’ costs for contact dermatitis* and pressure ulcers’ prophylaxis and treatment
with one immobile urinary-incontinent patient without absorbing means and skin
care agents applying are considerably higher (by 41%) than when they are applied.
At the same time indirect costs including linen disinfection, washing, drying and
ironing were not taken into account and such costs can increase a costs’ total
figure. CONCLUSIONS:Absorbent means and skin care agents’ application for con-
tact dermatitis and pressure ulcers prophylaxis and treatment with immobile uri-
nary-incontinent patients is a dominant technique and cost efficacy of using ab-
sorbent means and skin care agents was demonstrated. The Branch standard
“Patients’ management protocol. Pressure ulcers” (2002) needs actualization taking
into account the data obtained in the present clinical-economic research.
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OBJECTIVES: To quantify the financial effects of the introduction of a recommen-
dation for rotavirus vaccination in Saxony, Germany, in 2008 using a retrospective
data analysis. Special emphasis is given to the herd effect.METHODS:We analyzed
the costs of rotavirus infection between 2007 and 2010 based on 360.000 observa-
tions from the AOK Plus of children under 5 years for Saxony. To investigate the
cost impact of the regional recommendation, we compared the associated costs of
the expected annual RVGE cases derived from 2005 when rotavirus vaccination was
not yet available, with the actual annual number of RVGE cases, vaccinations and
associated costs per age cohort. A decrease in RVGE cases in not vaccinated cohorts
was attributed to herd effect. We make distinction between in- and outpatient
cases, societal and SHI perspective as well as different age groups. RESULTS: Given
that the vaccination rate has increased from 5% to 61% in the observed period, we
obtained following estimates: the mean total cost reduction per year attributable to
introducing a recommendation for rotavirus vaccination is 4.5 million € (2.4 million
€) from the societal (SHI) perspective. The mean cost savings of vaccination per
avoided case rise from 572 € (291 €) in 2007 to 718 € (375 €) in 2010. The overall share
of outpatient costs is about 72% (60%). About 45% of the total savings is attributable
to herd effect. The herd effect per avoided case decreases over time while immu-
nity increases. CONCLUSIONS: A recommendation for rotavirus vaccination in
Saxony turns out to be cost saving from the SHI as well as the societal perspective.
This is mainly attributed to the herd effect being present when having high vacci-
nation rates.
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OBJECTIVES: To determine the relationship of polypharmacy on blood pressure
(BP) control, compliance, persistence, the cost and incidence of cardiovascular
events (CVD) in patients with moderate/severe hypertension. METHODS: An ob-
servational multicenter retrospective study. We evaluated patients 30 years who
started a third antihypertensive treatment during 2004-2006. Depending on the
number of chronic medications, we established 3 groups: regular consumption of
3-6 drugs, between 7-10 and 11. Top measures: sociodemographic, comorbidity,
BP, compliance and persistence. For each group we determined the incidence of
new CVD and total costs. Patients were followed for 4 years. RESULTS: We evalu-
ated 1,906 patients, 765 between 3-6 drugs, 624 between 7-10 and 517 in _ 11 (P 
0.001). Overage age: 69.4 years and 55.5% women. The group of 3-6 drugs showed
better BP control (51.8 vs. 47.0 and 41.1%, P  0.001), compliance (71.4 vs. 69.9 and
67.1%, P 0.017), persistence (50.1 vs. 45.5 and 46.2%, P 0.044) and lower incidence
of CVD (12.2 vs. 19.7 and 30.2%, P 0.001), respectively. The average/unit total cost
was 3,369.1 vs. 4,362.1 and s 4,902.3 (P 0.001). The presence of CVD was associated
with therapy non-compliance (odds ratio [OR] 1.9, 95% confidence interval [95% CI]
1.1 to 3.6) and lower BP control (OR 1.4 [95% CI 1.1-2.0], P  0.05). The use of anti-
hypertensive fixed dose has greater compliance (72.8 vs. 68.2%), persistence (64.4
vs. 39.3%) and degree of BP control (52.6 vs. 43, 8%), P  0.001. CONCLUSIONS:
Polypharmacy is associated with lower compliance and persistence to antihyper-
tensive treatment, cardiovascular disease and increased health care costs.
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OBJECTIVES:We estimated the impact of influenza A(H1N1)2009 infection in terms
of patient’s health care services utilization, work absenteeism and costs, both dur-
ing the pandemic (2009-10) and postpandemic-seasonal (2010-11) waves in Spain.
METHODS: Longitudinal, multi-centre study of in- and outpatients with RT-PCR
confirmed diagnosis of influenza at pandemic(PAND) and postpandemic-season-
al(POST) waves. Health care and social resources utilization were the main vari-
ables, together with clinical and sociodemographic characteristics. Evaluations
were conducted at hospital-admission or ambulatory index-visit, and after recov-
ery (median100 days). Unitary costs and Monte Carlo simulation were applied to
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estimate costs for in-and outpatients. RESULTS: Among the 264_PAND and
132_POST inpatients, 30% were 18 years old, and 45% were women. The mean
length of stay at general ward was of 6.5(6.1)-7.0(6.6) days (PAND and POST, respec-
tively); and between 8.2(5.0) and 11.5(15.2) days for ICU patients (7%_PAND and
20%_POST). Among employed (45.3% PAND and 37.7% POST) most went on sick
leave (99% and 93%) for about 31(37) and 38(27) days. Among outpatients
(215_PAND and 175_POST), about 25-35% were under 17 years old, and 50-57% were
women. The 94%(PAND) and 82%(POST) of employed (64,9% and 68,0%, respec-
tively) went on sick leave. Absenteeism length of was 11(12)-7(45) days. The mean
cost per inpatient was 6,028 € (SD6,251) in PAND and 6,939€(SD10,895) in POST.
For outpatients the mean cost was 749€ (SD886) in PAND and 421€ (SD686) in
POST. CONCLUSIONS: Contrary to what expected, resource utilization was quite
similar for both influenza waves. However, differences on mean cost were found
due to the slightly increase in inpatients health care utilization, and the decrease of
absenteeism among outpatients during the post-pandemic wave. These results
would be useful to assess the influenza real burden in Spain; both at individual and
population level.
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OBJECTIVES: To estimate direct medical costs of atopic dermatitis (AD) from a US
payer perspective. METHODS: Data came from a large employer-based longitudi-
nal claims database, which captures person-specific clinical utilization, expendi-
tures, and enrollment across inpatient, outpatient, prescription drug, and carve-
out services. A matched case-control study design was employed. Cases were
identified based on at least two AD-related medical claims with an International
Classification of Disease v9 codes of 691.8x or 692.x anytime during the calendar
year of 2009. Three controls were matched to each case based on age, gender, type
of health plan enrolled, and censes region. Multivariate robust regression models
were used to estimate the incremental burden of AD. A non-parametric bootstrap
technique with 1000 replications was used to estimate the distribution of the beta
coefficients and derive the 95% confidence limits. RESULTS:A total of 119,252 cases
were matched to 357,756 controls with an average age of 46 years (SD23.9), and
57% females. AD-related comorbidities such as allergic rhinitis, asthma, other
types of allergies, sleep disturbances and attention deficit disorders were signifi-
cantly greater (p0.01) in proportion among cases vs. controls. After adjusting for
all baseline differences, cases on an average had $912 (95% CL:$781-$1,042) greater
overall cost per subject compared to controls. Top three drivers were attributed to
outpatient costs (58%, $533), inpatient costs (22%, $201), and pharmacy costs (15%,
$139), respectively. Among cases, dermatology-related overall costs were 370%
(from $127 to $470) greater post index event. Over 80% of this increase was attrib-
utable to dermatology-related outpatient costs. Approximately, three additional
dermatology-related outpatient visits were observed in the follow-up period com-
pared to baseline. CONCLUSIONS: AD is costing the U.S. payer an additional $912
per-patient-per-year compared to subjects with no AD. Future research should
determine the impact of current treatment on the economic burden of this disease.
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OBJECTIVES: The economic burden of heart failure (HF) has increased rapidly with
the increasing prevalence and incidence of HF patients all around the world. In this
abstract, the cost analysis of hospitalized HF patients is presented. METHODS: A
sample of hospitalizations (n166, year 2011) with diagnoses related with chronic
HF in a state hospital serving to a wide range of populations was evaluated. The
prices for ICU stay and cardiovascular procedures paid by Turkish state health
security system were applied. Indirect costs are not taken into account. RESULTS:
Twelve percent of the stays were in intensive care unit (ICU), 35% were in medical
ward only and 53% of the stays were partly in ICU and medical ward; average
duration were 2.513.09 days, 4.454.07 days and 6.955.08 days, respectively. ICU
stays are paid with fixed prices, without allowance for any extra payment for
services or procedures performed while the patient stays in ICU. Average daily and
total costs of ICU stay are calculated as 402€/day and 1006€, respectively. On the
other hand, procedures are paid per service, while the patient stays in medical
ward. Therefore the fixed amounts of payments for cardiovascular procedures,
which are mostly performed during the stay of HF patients, were averaged by the
frequencies of individual procedures. This yielded to 531€ per stay. Therefore the
total cost of stay was obtained as 1537€, and average daily cost of stay as 221€/day.
CONCLUSIONS: These figures are quite concordant with a previous analysis re-
ported in 2009 (total cost of stay 1617€ and daily cost of stay 245€/day) in which
micro-costing methods had been applied. Therefore these figures presented in this
report could be used local input parameters for health economics models for HF.
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OBJECTIVES: Inappropriate shocks are the most common complications of ICD,
causing a negative effect on patients’ morbidity and mortality. Little is known with
regards to the cost associated to the management of IS. The aim of the study was to
determine IS related factors and to evaluate its associated hospital cost.METHODS:
All patients implanted with an ICD where retrospectively analyzed through clinical
chart reviews in a Spanish hospital from 2003 to 2011. Demographic variables,
baseline cardiomyopathy, comorbidities, indication and type of ICD implanted
were registered. During the follow up period we identified the presence of IS, its
reasons and associated costs. RESULTS: A total of 227 patients were implanted
with an ICD, mean age 63.2 years (26-82). Eighty-six percent were men, 64.6% with
ischemic cardiomyopathy, 78.4% with heart failure, 70.4% with EF35% and 13.1%
with AF. The proportion of single, dual and three chambers ICD was 54.6%, 20.3%
and 25.1% respectively. After a median follow up of 4.46 years, 27 patients had had
42 IS episodes. Average time since implant to first IS was 1.3 years (range 0.02 to 3.84
years). Patients suffering from IS had higher mortality (33.3% vs 13.7%; p0.05).
Amost 67% of the episodes were due to supraventricular tachycardia, 12% to noise
detection, 19% to Wave T overdetection and 2.3% due to other causes. Sixty-three
percentages of the episodes generated an emergency visit and a 39% generated a
non-scheduled visit to the cardiologist. Seven episodes (16.7%) required hospital-
ization, six of whom required a surgical intervention. Average length of stay was
5.1 days. Finally, overall mean hospital cost appeared to be €5,175 per episode.
CONCLUSIONS: The cost of inappropriate shocks is driven by the reason of its
cause. The great majorities of the episodes were due to supraventricular arrhyth-
mias and finally resolved without the need for hospitalization.
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OBJECTIVES: To assess out-of-pocket expenses reported by patients receiving
chronic treatment for atrial fibrillation (AF) in five European countries. METHODS:
The EUPS-AF questionnaire was adapted from the 2008 Commonwealth Fund In-
ternational Health Policy Survey of Chronically Ill Adults. Computer-assisted digi-
tal telephone dialling was used to screen a random sample from the entire adult
populations of France, Germany, Italy, Spain and the UK. Structured telephone
interviews were conducted between February and July 2011. RESULTS: Interviews
were conducted with 1507 patients (France, n300; Germany, n300; Italy, n302;
Spain, n305; UK, n300). On average, 40% of patients had incurred no out-of-
pocket expenses for medical treatment or services over the past 12 months (range,
18% [Italy] to 75% [UK]). Of the 582 patients who reported out-of-pocket expenses
(mean, €705), 221 (44%) declared that the costs included those due to AF (mean,
€466). The lowest mean out-of-pocket cost per patient for AF care was reported in
France (€92 [median, €82], n14) and the highest in the UK (€1573 [median, €114],
n29). The majority of out-of-pocket expenses for AF were non-medical costs for
treatment and services not covered by insurance, including travel and household
help. The proportion of patients who claimed cost as a reason for not filling a
prescription or skipping doses ranged from 3% in the UK and Spain to 10% in
France. Failure to receive treatment due to lack of reimbursement was experienced
least frequently in the UK (1% of patients) and most frequently in Germany (28% of
patients). CONCLUSIONS: The EUPS-AF highlights differences in out-of-pocket ex-
penses and levels of treatment reimbursement that patients with AF have to pay in
five European countries. Payers, health care policy makers and clinicians should all
be aware that the financial burden of AF is linked to treatment adherence and may
affect patient satisfaction and treatment outcome.
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OBJECTIVES: Streptococcus pneumoniae causes a wide spectrum of illness from
upper respiratory tract infection to severe invasive pneumococcal disease (IPD),
defined as the identification of S. pneumoniaea normally sterile site. The most
severe IPD forms are meningitis, bacteraemia and septicaemia. Older adults are in
an increased risk of death from IPD. The former socialistic countries of the central
Europe form a unique region with specific health care and epidemiology charac-
teristics, and where the local evidence on the underlying epidemiology is scarce.
The objective was to estimate the economic burden of IPD in those50 years of age
in the Czech Republic (CR), Slovakia (SK), Poland (PL), and Hungary (HU) using most
recent data available. METHODS: The incidence of IPD stratified by age groups
50-64, 65-74, 75-84 and 85 was obtained from national surveillance systems (PL,
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